3-hydroxykynurenine has been researched along with Depression in 5 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate if there is a correlation between serum kynurenines levels with poststroke anxiety and depression symptoms and disability scales." | 7.96 | Serum Kynurenines Correlate With Depressive Symptoms and Disability in Poststroke Patients: A Cross-sectional Study. ( Barajas-Martínez, K; Carrillo-Mora, P; Estrada-Cortés, B; Franyutti-Prado, K; Gamboa-Coria, G; Martínez-Cortéz, JA; Pérez-De la Cruz, V; Quinzaños-Fresnedo, J; Ramírez-Ortega, D; Ramos-Chávez, LA; Rangel-Caballero, F; Rodríguez-Barragán, M; Sánchez-Chapul, L; Sánchez-Vázquez, I; Toussaint-González, P, 2020) |
| "A cross-sectional case-control study was conducted in patients with first stroke, of >1 month and <1 year of evolution, with no history of previous psychiatric or neurological disorders; the Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), functional evaluations (Barthel index, Functional Independence Measure [FIM]) were applied and serum kynurenines (Kyns) were determined." | 7.96 | Serum Kynurenines Correlate With Depressive Symptoms and Disability in Poststroke Patients: A Cross-sectional Study. ( Barajas-Martínez, K; Carrillo-Mora, P; Estrada-Cortés, B; Franyutti-Prado, K; Gamboa-Coria, G; Martínez-Cortéz, JA; Pérez-De la Cruz, V; Quinzaños-Fresnedo, J; Ramírez-Ortega, D; Ramos-Chávez, LA; Rangel-Caballero, F; Rodríguez-Barragán, M; Sánchez-Chapul, L; Sánchez-Vázquez, I; Toussaint-González, P, 2020) |
| "To investigate if there is a correlation between serum kynurenines levels with poststroke anxiety and depression symptoms and disability scales." | 3.96 | Serum Kynurenines Correlate With Depressive Symptoms and Disability in Poststroke Patients: A Cross-sectional Study. ( Barajas-Martínez, K; Carrillo-Mora, P; Estrada-Cortés, B; Franyutti-Prado, K; Gamboa-Coria, G; Martínez-Cortéz, JA; Pérez-De la Cruz, V; Quinzaños-Fresnedo, J; Ramírez-Ortega, D; Ramos-Chávez, LA; Rangel-Caballero, F; Rodríguez-Barragán, M; Sánchez-Chapul, L; Sánchez-Vázquez, I; Toussaint-González, P, 2020) |
| "A cross-sectional case-control study was conducted in patients with first stroke, of >1 month and <1 year of evolution, with no history of previous psychiatric or neurological disorders; the Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), functional evaluations (Barthel index, Functional Independence Measure [FIM]) were applied and serum kynurenines (Kyns) were determined." | 3.96 | Serum Kynurenines Correlate With Depressive Symptoms and Disability in Poststroke Patients: A Cross-sectional Study. ( Barajas-Martínez, K; Carrillo-Mora, P; Estrada-Cortés, B; Franyutti-Prado, K; Gamboa-Coria, G; Martínez-Cortéz, JA; Pérez-De la Cruz, V; Quinzaños-Fresnedo, J; Ramírez-Ortega, D; Ramos-Chávez, LA; Rangel-Caballero, F; Rodríguez-Barragán, M; Sánchez-Chapul, L; Sánchez-Vázquez, I; Toussaint-González, P, 2020) |
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "A subgroup of individuals with mood and psychotic disorders shows evidence of inflammation that leads to activation of the kynurenine pathway and the increased production of neuroactive kynurenine metabolites." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| " In contrast, schizophrenia and psychosis are hypothesized to arise from increased metabolism of the NMDA receptor antagonist, kynurenic acid (KynA), leading to hypofunction of GABAergic interneurons, the disinhibition of pyramidal neurons and striatal hyperdopaminergia." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 1.46 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrillo-Mora, P | 1 |
| Pérez-De la Cruz, V | 1 |
| Estrada-Cortés, B | 1 |
| Toussaint-González, P | 1 |
| Martínez-Cortéz, JA | 1 |
| Rodríguez-Barragán, M | 1 |
| Quinzaños-Fresnedo, J | 1 |
| Rangel-Caballero, F | 1 |
| Gamboa-Coria, G | 1 |
| Sánchez-Vázquez, I | 1 |
| Barajas-Martínez, K | 1 |
| Franyutti-Prado, K | 1 |
| Sánchez-Chapul, L | 1 |
| Ramírez-Ortega, D | 1 |
| Ramos-Chávez, LA | 1 |
| Wurfel, BE | 1 |
| Drevets, WC | 1 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 1 |
| Morris, HM | 1 |
| Teague, TK | 1 |
| Dantzer, R | 1 |
| Savitz, JB | 1 |
| Buras, A | 1 |
| Waszkiewicz, N | 1 |
| Szulc, A | 1 |
| Haverkamp, GL | 1 |
| Loosman, WL | 1 |
| Franssen, CF | 1 |
| Kema, IP | 1 |
| van Diepen, M | 1 |
| Dekker, FW | 1 |
| Honig, A | 1 |
| Siegert, CE | 1 |
| Clark, JA | 1 |
| Clark, MS | 1 |
| Palfreyman, ES | 1 |
| Palfreyman, MG | 1 |
1 review available for 3-hydroxykynurenine and Depression
| Article | Year |
|---|---|
[Depression and inflammation in rheumatic diseases].
Topics: Cytokines; Depression; Humans; Hypothalamo-Hypophyseal System; Indoleamine-Pyrrole 2,3,-Dioxygenase; | 2016 |
4 other studies available for 3-hydroxykynurenine and Depression
| Article | Year |
|---|---|
Serum Kynurenines Correlate With Depressive Symptoms and Disability in Poststroke Patients: A Cross-sectional Study.
Topics: Adult; Aged; Case-Control Studies; Cross-Sectional Studies; Depression; Female; Functional Status; H | 2020 |
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
The role of tryptophan degradation in the association between inflammatory markers and depressive symptoms in chronic dialysis patients.
Topics: Adult; Aged; Biomarkers; C-Reactive Protein; Depression; Female; Glomerulonephritis; Humans; Inciden | 2017 |
The effect of tryptophan and a tryptophan/5-hydroxytryptophan combination on indoles in the brains of rats fed a tryptophan deficient diet.
Topics: 3-Hydroxyanthranilic Acid; 5-Hydroxytryptophan; Animals; Brain; Depression; Diet; Drug Synergism; Hu | 1975 |